GenScript Biotech's MSCI ESG Rating Upgraded to AA, Recognized as a Global Leader

Core Viewpoint - GenScript Biotech Corporation has received an upgraded ESG rating of AA from MSCI, reflecting its strong commitment to sustainability and responsible business practices in the biotech industry [1][2][3]. Group 1: ESG Rating and Recognition - The AA rating from MSCI positions GenScript as a global leader in ESG, highlighting its excellence in product safety, quality, and human capital development [1][2]. - GenScript's sustainability initiatives have been recognized through various accolades, including a Silver Medal from EcoVadis and inclusion in the FTSE4Good Index Series [3]. Group 2: Commitment to Sustainability - The company is a participant in the United Nations Global Compact, adhering to principles on human rights, labor, environment, and anti-corruption [3]. - GenScript's carbon reduction targets have been validated by the Science Based Targets initiative (SBTi), showcasing its commitment to combating climate change [3]. Group 3: Company Overview - Founded in 2002, GenScript Biotech Corporation employs over 5,500 individuals and has served more than 200,000 customers across 100 countries [4]. - The company's mission is to enhance health for people and nature through biotechnology, positioning it as a trusted global leader in the industry [4].